Autres langues Magenta Therapeutics

Actions

MGTA

US55910K1088

Marché Fermé - Nasdaq 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
101,12 ^USD	-1,34 %		-2,09 %	+803,37 %

11/09/23	Dianthus Therapeutics, Inc. a finalisé l'acquisition de Magenta Therapeutics, Inc. (NasdaqGM:MGTA) auprès d'un groupe d'actionnaires dans le cadre d'une opération de fusion inversée.	CI
03/08/23	Magenta Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI

Autres langues

11/09/23	Adrenoleukodystrophy Clinical Trials, and Key Companies\|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
11/09/23	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index
11/09/23	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
07/08/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
03/08/23	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index
19/05/23	Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer
15/05/23	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
04/05/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
03/05/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
03/05/23	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
03/05/23	Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.
06/04/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)
06/04/23	Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc
31/03/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
31/03/23	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
23/03/23	MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
07/02/23	MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)
07/02/23	Magenta Therapeutics, Inc. Announces Management Changes
07/02/23	Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer
03/02/23	Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
03/02/23	Top Premarket Gainers